Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 16/20 | 0.54 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588242 | 0.91 | ATR (0.53) | ATRTDO2PDCD1CD274PIK3CD | |
| SCHEMBL3603991 | 0.87 | ATR (0.49) | ATRTDO2PDCD1CD274PIK3CD | |
| SCHEMBL3609335 | 0.85 | ATR (0.48) | ATRTDO2PDCD1CD274PIK3CD | |
| SCHEMBL1029284 | 0.83 | ATR (0.55) | ATRTDO2PDCD1CD274PIK3CD | |
| SCHEMBL17309137 | 0.83 | ATR (0.57) | ATRTDO2PDCD1CD274PIK3CD | |
| SCHEMBL368719 | 0.83 | ATR (0.48) | ATRPDCD1CD274PIK3CDCYP3A4 | |
| SCHEMBL3609331 | 0.83 | ATR (0.47) | ATRTDO2PDCD1CD274CHEK1 | |
| SCHEMBL1026280 | 0.83 | NPSR1 (0.59) | ATRTDO2PIK3CD | |
| SCHEMBL1027578 | 0.82 | AKT1 (0.46) | ATRTDO2 | |
| SCHEMBL1028524 | 0.81 | ATR (0.62) | ATRPDCD1CD274CHEK1ATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | claimed |
| EP-2150546-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. Hoffmann-Roche AG (CH) | 2010-02-10 | — | — | EP | claimed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | claimed |
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130496-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIK3CA, PIP5K1B, PIK3CD | ATR 453/4885TDO2 2129/4885PDCD1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.